Innoviva Specialty Therapeutics

Innoviva Specialty Therapeutics is owned by Innoviva.

Innoviva is one of the...

• Russell 3000.

Innoviva is a company listed under the stock ticker INVA (US).

They are in:

• Pharmaceuticals50%
• Biotechnology50%

Acquisition, funding and merger involving Innoviva.

• Innoviva has announced the acquisition of Entasis Therapeutics  (posted on May 24 2022).

View the org chart displaying its 4 main executives

Most searched biographies at Innoviva Specialty Therapeutics

• Matt Ronsheim, Chief Technical Officer
• David Altarac, Chief Medical Officer
• Christine Coyne, Chief Commercial Officer

Popular executive movements at Innoviva

• Stephen Basso has joined the company as Chief Financial Officer  (posted on August 28 2023).

Create your alert
to follow the executive moves at Innoviva Specialty Therapeutics.

Innoviva has 2,289 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Attovia Therapeutics has just announced a $150 Million fundraising (posted on May 14 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on May 13 2024).
• Aardvark Therapeutics has just announced a $85 Million fundraising (posted on May 12 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Carl Gordon - Director at Adicet Bio
• Vik Bajaj - Director at Interline Therapeutics

Learn more about the Biotechnology industry >

Press releases by Innoviva Specialty Therapeutics

Social media about Innoviva Specialty Therapeutics

• Innoviva Specialty Therapeutics on Wikipedia, Google News & Yahoo Finance
• Innoviva Specialty Therapeutics on LinkedIn, Twitter & YouTube

Call Innoviva Specialty Therapeutics at +1 857...

View the org chart

Register to receive your alert

Report an error